Comparison Overview

ASP Cares Pharmacy

VS

Novo Nordisk

ASP Cares Pharmacy

None
Last Update: 2025-03-06 (UTC)
Between 800 and 900

Strong

About the Company ASP Cares has specialty pharmacies located across the U.S. and corporate headquarters in Farmers Branch, Texas. Philosophy Weโ€™re committed to improving the health and well-being of individuals and communities through a patient-centered approach of compassion, personal attention, and quality care. We partner with the patientโ€™s entire healthcare team, navigating communication between patients, physicians, insurance companies, and manufacturers to ensure the most appropriate prescription drug treatment at the most affordable price. Specialty Services ASP Cares excels in medication therapies that require specialized compounding, complex administration, and/or high cost. As patient advocates, our professionals offer compassionate consultation, prior authorization coordination, financial assistance, and free delivery. Our pharmacy staff are highly knowledgeable in advanced therapies for complicated health issues including: Dermatology, Gastroenterology, Hemophilia, Hepatitis, HIV/AIDS, Multiple Sclerosis, Oncology, Pulmonary Hypertension, Rheumatology, Transplant, and Urology. Careers Itโ€™s an exciting time at ASP Cares. Weโ€™re experiencing explosive growth and always looking for bright, collaborative people to join our team. We pride ourselves on our โ€˜familyโ€™ environment based on teamwork. Accreditation The company is accredited by the Accreditation Commission for Health Care (ACHC), Utilization Review Accreditation Commission (URAC), and American Board for Certification Facility. These accreditations demonstrate that our organization meets predefined criteria and is dedicated to improving healthcare.

NAICS: 325
NAICS Definition:
Employees: 78
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Novo Nordisk

Novo Alle, Bagsvรฆrd, undefined, 2880, DK
Last Update: 2025-05-06 (UTC)

Strong

Between 800 and 900

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isnโ€™t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordiskโ€™s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 64,615
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/aspcares.jpeg
ASP Cares Pharmacy
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
ASP Cares Pharmacy
100%
Compliance Rate
0/4 Standards Verified
Novo Nordisk
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for ASP Cares Pharmacy in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Novo Nordisk in 2025.

Incident History โ€” ASP Cares Pharmacy (X = Date, Y = Severity)

ASP Cares Pharmacy cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Novo Nordisk (X = Date, Y = Severity)

Novo Nordisk cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/aspcares.jpeg
ASP Cares Pharmacy
Incidents

No Incident

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
Incidents

No Incident

FAQ

Both ASP Cares Pharmacy company and Novo Nordisk company demonstrate a comparable AI risk posture, with strong governance and monitoring frameworks in place.

Historically, Novo Nordisk company has disclosed a higher number of cyber incidents compared to ASP Cares Pharmacy company.

In the current year, Novo Nordisk company and ASP Cares Pharmacy company have not reported any cyber incidents.

Neither Novo Nordisk company nor ASP Cares Pharmacy company has reported experiencing a ransomware attack publicly.

Neither Novo Nordisk company nor ASP Cares Pharmacy company has reported experiencing a data breach publicly.

Neither Novo Nordisk company nor ASP Cares Pharmacy company has reported experiencing targeted cyberattacks publicly.

Neither ASP Cares Pharmacy company nor Novo Nordisk company has reported experiencing or disclosing vulnerabilities publicly.

Neither ASP Cares Pharmacy company nor Novo Nordisk company has publicly disclosed detailed information about the number of their subsidiaries.

Novo Nordisk company employs more people globally than ASP Cares Pharmacy company, reflecting its scale as a Pharmaceutical Manufacturing.

Latest Global CVEs (Not Company-Specific)

Description

MinIO is a high-performance object storage system. In all versions prior to RELEASE.2025-10-15T17-29-55Z, a privilege escalation vulnerability allows service accounts and STS (Security Token Service) accounts with restricted session policies to bypass their inline policy restrictions when performing operations on their own account, specifically when creating new service accounts for the same user. The vulnerability exists in the IAM policy validation logic where the code incorrectly relied on the DenyOnly argument when validating session policies for restricted accounts. When a session policy is present, the system should validate that the action is allowed by the session policy, not just that it is not denied. An attacker with valid credentials for a restricted service or STS account can create a new service account for itself without policy restrictions, resulting in a new service account with full parent privileges instead of being restricted by the inline policy. This allows the attacker to access buckets and objects beyond their intended restrictions and modify, delete, or create objects outside their authorized scope. The vulnerability is fixed in version RELEASE.2025-10-15T17-29-55Z.

Risk Information
cvss3
Base: 8.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:N
Description

Envoy is an open source edge and service proxy. Envoy versions earlier than 1.36.2, 1.35.6, 1.34.10, and 1.33.12 contain a use-after-free vulnerability in the Lua filter. When a Lua script executing in the response phase rewrites a response body so that its size exceeds the configured per_connection_buffer_limit_bytes (default 1MB), Envoy generates a local reply whose headers override the original response headers, leaving dangling references and causing a crash. This results in denial of service. Updating to versions 1.36.2, 1.35.6, 1.34.10, or 1.33.12 fixes the issue. Increasing per_connection_buffer_limit_bytes (and for HTTP/2 the initial_stream_window_size) or increasing per_request_buffer_limit_bytes / request_body_buffer_limit can reduce the likelihood of triggering the condition but does not correct the underlying memory safety flaw.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
Description

In Xpdf 4.05 (and earlier), a PDF object loop in a CMap, via the "UseCMap" entry, leads to infinite recursion and a stack overflow.

Risk Information
cvss4
Base: 2.1
Severity: HIGH
CVSS:4.0/AV:L/AC:H/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was identified in NucleoidAI Nucleoid up to 0.7.10. The impacted element is the function extension.apply of the file /src/cluster.ts of the component Outbound Request Handler. Such manipulation of the argument https/ip/port/path/headers leads to server-side request forgery. The attack may be performed from remote.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

HCL Traveler for Microsoft Outlook (HTMO) is susceptible to a credential leakage which could allow an attacker to access other computers or applications.

Risk Information
cvss3
Base: 5.5
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N